[{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Candid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Candid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Candid Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mount Sinai Health System"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Nona Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ABBV-47D11","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tanfanercept","moa":"TNF-alpha receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Ingenia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Ingenia Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Hudson Bay Capital"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ CSPC Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ CSPC Pharmaceutical Group"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HBM9167","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ SK Holdings"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Cullinan Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mythic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Mythic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Mythic Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ PharmaEssentia","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ PharmaEssentia"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Alkyon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Alkyon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Alkyon Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Boostimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Boostimmune","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Boostimmune"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Dragonfly Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Dragonfly Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Umoja Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ Umoja Biopharma"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"UAB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ UAB","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ UAB"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"HBM7022","moa":"CLDN18.2\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Kodiak Sciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ BlackRock Fund"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Lycia Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Atossa Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Atossa Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Nona Biosciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
